Document is current
Any future updates will be listed below
-
Authors
Dias, Chloé https://orcid.org/0000-0003-0461-0116
Ballout, Nissrine https://orcid.org/0000-0001-8301-3170
Morla, Guillaume https://orcid.org/0009-0001-0119-7090
Alileche, Katia https://orcid.org/0009-0002-4898-4021
Santiago, Christophe https://orcid.org/0009-0007-4994-5127
Guerrera, Ida Chiara https://orcid.org/0000-0002-4832-6793
Chaubet, Adeline https://orcid.org/0009-0003-9326-0935
Ausseil, Jerome https://orcid.org/0000-0002-3059-9777
Trudel, Stephanie https://orcid.org/0000-0003-1202-415X
-
Funding
Funding for this research was provided by:
Association Vaincre les Maladies Lysosomales, France
Institut National de la Santé et de la Recherche Médicale
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 7 October 2024
First Online: 4 November 2024
Declarations
:
: In line with the French Public Health Code (<i>Code de la Santé Publique</i>, article L1211-2), the parents and/or their legal guardians of under-18 MPSIII patients and of under-18 healthy control volunteers stated that they did not object to the use of urine samples for biomedical research. Mouse experiments were performed by authorized investigators in accordance with French regulations and the European Union Council Directive 86/609/EEC and were approved by the government-accredited animal care and use committee (<i>Comité d’Ethique de l’US 006/CREFRE</i> (Toulouse, France); reference number: PI-U1291-JA-37).
: Not applicable.
: The authors declare no competing interests.
